Katy Peters, MD, PhD
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (NCT05609994) | Katy Peters, MD, PhD | 2025-07-15 |
| IDH1 Peptide Vaccine for Recurrent Grade II Glioma (NCT02193347) | Katy Peters, MD, PhD | 2016-01-28 |
Track Katy Peters, MD, PhD automatically
Every clearance here is in the API, with alerts when new ones post.